TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Artesunate-amodiaquine and Artemether-lumefantrine for Uncomplicated Malaria in South Kivu, DR Congo

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age between 6 and 59 months~* Weight ≥ 5 Kg~* Slide-confirmed infection with Plasmodium falciparum only (no mixed infections)~* Asexual parasite density between 2000 and 200000/µl of blood~* Measured axillary temperature ≥ 37.5°C~* Ability to swallow oral medication~* High probability of respecting the follow-up visits (residence within 1 hour walking distance from the OPD, no upcoming travel plans, etc.)~* Informed consent from a parent or caretaker aged at least 18 years.~Exclusion Criteria:~* • General danger signs according to the WHO definition (Appendix 5.1.1)~  * Signs of severe/complicated malaria according to the WHO definition (Appendix 5.1.2)~ * Severe anaemia (haemoglobin \< 5 g/dL)~ * Known history of hypersensitivity to any of the study drugs~ * Severe acute malnutrition (as defined by a weight-for-height below -3 Z-score and/or symmetrical oedemas involving at least the feet)~ * Concomitant febrile illness due to causes other than malaria with the potential to confound study outcome (measles, acute lower tract respiratory infection, otitis media, tonsillitis, abscesses, severe diarrhoea with dehydration).~ * Having received already a full course of the treatment (or one of the treatments) under study in the previous 28 days (as indicated by the parent/caretaker). Note that previous incomplete anti-malarial intake of treatments under study, or previous intake of anti-malarials not under study, are not exclusion criteria, but details of any such intake should be recorded carefully.~ * History of hypersensitivity reactions or contra-indications to any medicines being tested.

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 59 Months
- Healthy Volunteers: f

Study Arms:
- Amodiaquine-Artesunate (ASAQ) (Type: ACTIVE_COMPARATOR): Treatment regimen consisted of Amodiaquine-Artesunate (ASAQ) fixed dose (FD) (Winthrop Sanofi Aventis), given as 1 tablet/day 3 days (5-8 kg 1 tab of 25mg artesunate/67.5 mg amodiaquine base, 9-17 kg 50 mg artesunate/135 mg amodiaquine base)
- Artemether-Lumefantrine (AL) (Type: ACTIVE_COMPARATOR): Treatment consisted of Artemether-Lumefantrine (AL) (Coartem, Novartis) given as six twice/daily doses over three days (5-14 kg 1tab of 20mg artemether/120mg lumefantrine BD, 15-24 kg 2tabs of 20mg artemether/120mg lumefantrine BD with fatty food).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Utilizing Qualitative and Quantitative Methods to Understand a New Model of Type 1 and 2 Systemic Lupus Erythematosus (SLE)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* All providers in Duke Rheumatology who practice outside of the Duke Lupus Clinic are eligible.~* Patients are eligible to participate if they have an established diagnosis of SLE and are followed in Duke Rheumatology.~* All patients with a SLE diagnosis will be included in the analysis. SLE diagnosis will be based on an ICD-10 code for SLE (M32.1\*, M32.8, M32.9) in the EMR.~Exclusion Criteria:~* New patients will be excluded

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SLE@Duke (Type: EXPERIMENTAL): Clinic providers in Duke Rheumatology outside of the Duke Lupus Clinic are eligible to participate in the SLE@Duke intervention. Participants complete a baseline survey and training in the Type 1 \& 2 SLE Model. They are asked to perform the intervention for all eligible patients over 4 weeks. Patients complete a survey at the end of their clinic visit, and providers complete a survey at the end of the 4 week intervention period. All participating providers were invited to an in-depth interview at the end of the intervention period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase 2 Study of ISIS 681257 (AKCEA-APO(a)-LRx) in Participants With Hyperlipoproteinemia(a) and Cardiovascular Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Key Inclusion Criteria:~* Clinical diagnosis of CVD defined as documented coronary artery disease, stroke, or peripheral artery disease~* Lp(a) plasma level ≥ 60 mg/dL~* Must be on standard-of-care preventative therapy for other than elevated Lp(a) CVD risk factors~Key Exclusion Criteria:~* Within 6 months of Screening: acute coronary syndrome, major cardiac surgery, or stroke/TIA~* Within 3 months of Screening: coronary, carotid, or peripheral arterial revascularization, major non-cardiac surgery, or lipoprotein apheresis~* Heart failure New York Heart Association (NYHA) class IV

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Cohort A: ISIS 681257: 20 mg Q4W (Type: EXPERIMENTAL): Cohort A participants received 20 milligrams (mg) ISIS 681257, subcutaneous (SC) injection, once every 4 weeks (Q4W), for up to 49 weeks and a maximum of 13 doses.
- Cohort B: ISIS 681257: 40 mg Q4W (Type: EXPERIMENTAL): Cohort B participants received 40 mg of ISIS 681257, SC injection, once Q4W, for up to 49 weeks and a maximum of 13 doses.
- Cohort C: ISIS 681257: 60 mg Q4W (Type: EXPERIMENTAL): Cohort C participants received 60 mg of ISIS 681257, SC injection, once Q4W, for up to 49 weeks and a maximum of 13 doses.
- Cohort D: ISIS 681257: 20 mg Q2W (Type: EXPERIMENTAL): Cohort D participants received 20 mg of ISIS 681257, SC injection, once every 2 weeks (Q2W), for up to 51 weeks and a maximum of 26 doses.
- Cohort E: ISIS 681257: 20 mg QW (Type: EXPERIMENTAL): Cohort E participants received 20 mg of ISIS 681257, SC injection, once weekly (QW), for up to 52 weeks and a maximum of 52 doses.
- Placebo (Type: PLACEBO_COMPARATOR): Participants in each cohort were randomized to receive placebo at a dose-matched volume of study drug (ISIS 681257).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Randomized Clinical Trial to Compare a Regimen of Trimethoprim-sulfamethoxazole Plus Rifampicin With a Regimen of Linezolid in the Treatment of Methicillin-Resistant Staphylococcus Aureus (MRSA) Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age \> 18 years~2. Patients with clinical signs and symptoms of MRSA-related infection~3. Culture of MRSA (predominant microorganism in culture) susceptible to all of the following:~   * TMP-SMX~  * rifampicin~  * linezolid~4. Patient must give written informed consent to participate in the study.~Exclusion Criteria:~1. Women who are pregnant or nursing~2. Women who refuse to substitute oral contraception during treatment~3. Known or suspected hypersensitivity to linezolid, TMP-SMX or rifampicin~4. Clinical or laboratory evidence of significant impairment of hepatic function, as demonstrated by any of the following criteria:~   * Bilirubin \> 3 x upper limit of normal range~  * AST or ALT \> 5 x upper limit of normal range~  * Acute hepatitis or proven liver cirrhosis by liver histology~5. Treatment with other antimicrobials with activity against MRSA for \> 72 hours prior to study inclusion~6. Patients with a high probability of death within the week following study entry~7. Patients who, in the opinion of the investigator, cannot be relied upon for post-therapy follow-up~8. Patients requiring alternative antibiotic therapy with anti-MRSA activity. However, if another antibiotic treatment without antistaphylococcal activity is necessary, the patient is acceptable for randomization. In that sense, the use of aztreonam (against Gram negative microorganisms) or metronidazole (against anaerobes) is allowed~9. Hemodialyzed patients~10. History of pheochromocytoma, carcinoid syndrome, untreated hyperthyroidism, uncontrolled hypertension, or patients receiving serotonin uptake inhibitors~11. Severe thrombocytopenia (\< 50.000 platelets)~12. Left-sided endocarditis with a poor prognosis (patients aged over 50; cerebral embolism)~13. Chronic osteomyelitis without surgical debridement; superinfected indwelling foreign body, deliberately kept in place~14. Patients with severe sepsis or septic shock due to MRSA bacteremia~15. Patients who receive any of the following drugs, which cannot be substituted or temporarily withdrawn: adrenergic and serotonergic agents, tramadol, pethidine, duloxetine, venlafaxine, milnacipran, sibutramine, chlorpheniramine, brompheniramine, cyproheptadine, citalopram, and paroxetine.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): trimethoprim-sulfamethoxazole (TMP-SMX) plus rifampicin
- 2 (Type: ACTIVE_COMPARATOR): Linezolid

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Investigational Drug Study in Patients With Type 2 Diabetes Mellitus (0431-024)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who are at least 18 years of age and not older than 78 with type 2 diabetes mellitus

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 78 Years
- Healthy Volunteers: f

Study Arms:
- Sitagliptin 100 mg (Type: EXPERIMENTAL): Sitagliptin 100 mg oral tablets of sitagliptin once daily.
- Glipizide (Type: ACTIVE_COMPARATOR): Glipizide 1 tablet (5 mg) per day. Patients could then up-titrated to a total daily dose of 4 tablets twice daily (20mg/day) based on their glycemic control.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Trial to Evaluate the Potential Impact of Renal Impairment on the Pharmacokinetics and Safety of CPX-351

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Ability to understand and voluntarily give informed consent.~2. Male or female patients, age ≥18 years at the time of consent.~3. Diagnosis of hematologic malignancy including, but not limited to, AML, ALL, and MDS. Patients may be newly diagnosed, refractory to initial treatment, or in relapse.~4. Patients with normal renal function, or moderate or severe renal impairment as categorized by creatinine clearance (CrCl)) using the Cockcroft-Gault Formula.~5. Consent of female patients to use a medically acceptable method of contraception for at least 2 months prior to the first dose of CPX-351 and consent of female patients to use a medically acceptable method of contraception throughout the entire study period and for 6 months following the last dose of CPX-351.~6. Male patients must be willing to refrain from sperm donation for 6 months following the last dose of CPX-351and must use adequate contraception throughout the entire study period and for 6 months following the last dose of CPX-351.~Exclusion Criteria:~1. Prior treatment with CPX-351 ≤ to 1 month before the start of CPX-351 in this study.~2. Patients with active (uncontrolled, metastatic) second malignancies are excluded.~3. Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent obtaining informed consent.~4. Patients with known hypersensitivity to cytarabine, daunorubicin, or liposomal products.~5. Female patients who are pregnant, nursing, or lactating.~6. Participation in another clinical trial of an investigational drug or medical device within 30 days or 5 half-lives (whichever is longer) prior to enrollment in this study.~7. Any other condition that would cause a risk to patients if they participate in the trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort 1 (Type: EXPERIMENTAL): Normal renal function
- Cohort 2 (Type: EXPERIMENTAL): Moderate renal impairment
- Cohort 3 (Type: EXPERIMENTAL): Severe renal impairment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Marijuana on Symptoms of OCD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Age 21-55~* Physically healthy~* Diagnosed with OCD~* Current marijuana user~* Women of childbearing potential must be using an effective form of birth control~* Not currently taking psychotropic medications~* Ability to provide informed consent~Exclusion Criteria:~* History of any significant medical condition that may increase the risk of participation~* Females who are pregnant or nursing~* If female, not pregnant~* Current or lifetime history of psychiatric disorders other than OCD that may increase the risk of participation~* Current substance use disorder~* Severe depression or positive urine toxicology (other than THC) at screening, or any adverse reaction to a cannabinoid~* Patients who are seeking treatment for substance abuse~* Patients who are planning to begin a course of cognitive-behavioral therapy within 8 weeks of beginning the study

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- High THC/Low CBD Marijuana (Type: EXPERIMENTAL): This condition involves the ingestion of marijuana with a high THC (5-10%) and low CBD (\<1%) content.
- Low THC/High CBD Marijuana (Type: EXPERIMENTAL): This condition involves the ingestion of marijuana with a low THC (\<1%) and high CBD (\>10%) content.
- No THC/No CBD (Type: PLACEBO_COMPARATOR): This condition involves the ingestion of a placebo control with no THC and no CBD content.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Forced-dose Titration of SPD489 in Adults With Binge Eating Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion~* Subject meets the following Diagnostic and Statistical Manual of Mental Disorders Fourth Edition - Text Revision (DSM-IV-TR) criteria for a diagnosis of binge eating disorder (BED).~* Binge eating disorder is of at least moderate severity in which subjects report at least 3 binge eating days per week.~* Subject has a body mass index (BMI) of \>24 and \<46.~Exclusion~* Subject has concurrent symptoms of bulimia nervosa or anorexia nervosa.~* Subject is considered a suicide risk or risk to harm others.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- SPD489 30 mg (Type: EXPERIMENTAL): None
- SPD489 50 mg (Type: EXPERIMENTAL): None
- SPD489 70 mg (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability, and Immunogenicity of Two Formulations of V114 in Healthy Adults 50 Years of Age or Older (V114-006)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Good health; any underlying chronic illness must be documented to be in stable condition~* Highly unlikely to conceive through 6 weeks after administration of the study vaccine~Exclusion Criteria:~* Prior administration of any pneumococcal vaccine~* History of invasive pneumococcal disease (IPD) \[positive blood culture, positive cerebrospinal fluid culture, or other sterile site) or known history of other culture-positive pneumococcal disease~* Known hypersensitivity to any vaccine component~* Known or suspected impairment of immune function~* Received systemic corticosteroids for \>=14 consecutive days and has not completed treatment \<=30 days prior to study entry, or received systemic corticosteroids exceeding physiologic replacement doses within 14 days prior to study vaccination~* Coagulation disorder contraindicating intramuscular vaccination~* Receives immunosuppressive therapy, including chemotherapeutic agents used to treat cancer or other conditions, and treatments associated with organ or bone marrow transplantation, or autoimmune disease~* Received a blood transfusion or blood products, including immunoglobulins within the 6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product within 30 days of receipt of study vaccine. Autologous blood transfusions are not considered an exclusion criterion.~* Participated in another clinical study of an investigational product within 2 months before the beginning of or any time during the duration of the current clinical study~* Breast feeding~* User of recreational or illicit drugs or has had a recent history (within the last year) of drug or alcohol abuse or dependence

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- V114 Formulation A (Type: EXPERIMENTAL): Participants receive a single 0.5 mL intramuscular injection of V114 Formulation A on Day 1
- V114 Formulation B (Type: EXPERIMENTAL): Participants receive a single 0.5 mL intramuscular injection of V114 Formulation B on Day 1
- Prevnar 13® (Type: ACTIVE_COMPARATOR): Participants receive a single 0.5 mL intramuscular injection of Prevnar 13® on Day 1

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Electrical Activation of The Diaphragm for Ventilatory Assist

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 years or older~* Cervical spinal cord injury dependent on mechanical ventilation~* Clinically stable following acute spinal cord injury~* Bilateral phrenic nerve function clinically acceptable as demonstrated with EMG recordings and nerve conduction times~* Diaphragm movement with stimulation visible under fluoroscopy~* Clinically acceptable oxygenation on room air (\>90%)~* Hemodynamically stable~* No medical co-morbidities that would interfere with the proper placement or function of the device~* Committed primary caregiver~* Negative pregnancy test in females of child-bearing potential~* Informed consent from patient or designated representative~Exclusion Criteria:~* Co-morbid medical conditions that preclude surgery~* Active lung disease (obstructive, restrictive or membrane diseases)~* Active cardiovascular disease~* Active brain disease~* Hemodynamic instability or low oxygen levels on room air~* Hospitalization for or a treated active infection within the last 3 months~* Significant scoliosis or chest deformity~* Marked obesity~* Anticipated poor compliance with protocol by either patient or primary caregiver~* Currently breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- NeuRx DPS (Type: EXPERIMENTAL): Laparoscopic implantation of 4 NeuRx DPS electrodes and subsequent pacing using the DPS system.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Exenatide as Monotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with type 2 diabetes~* Treating diabetes with diet and exercise~* HbA1c between 6.5% and 10.0%, inclusive~* Body Mass Index (BMI) between 25 kg/m\^2 and 45 kg/m\^2, inclusive~Exclusion Criteria:~* Have previously completed or withdrawn from this study~* Have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry~* Have been treated with any antidiabetic agent~* Have used drugs for weight loss (for example, Xenical, Meridia, Acutrim, or similar over-the counter medications) within 3 months of screening~* Are currently treated with any of the following excluded medications: \* drugs that directly affect gastrointestinal motility; \* systemic corticosteroids (excluding topical and inhaled preparations) by oral, intravenous, or intramuscular route used regularly (longer than 2 weeks) or used within 2 weeks immediately prior to screening for this study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Exenatide 5 mcg/exenatide 5 mcg (Type: EXPERIMENTAL): Exenatide 5 mcg; then exenatide 5 mcg
- Exenatide 5 mcg/exenatide 10 mcg (Type: EXPERIMENTAL): Exenatide 5 mcg, then exenatide 10 mcg
- Placebo (Type: PLACEBO_COMPARATOR): Placebo in volumes equivalent to exenatide

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete